Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.

Acid-reducing agents (ARAs) are the most commonly prescribed medications in North America and Western Europe. There are currently no data describing the prevalence of their use among cancer patients. However, this is a paramount question due to the potential for significant drug-drug interactions (DDIs) between ARAs, most commonly proton pump inhibitors (PPIs), and orally administered cancer therapeutics that display pH-dependent solubility, which may lead to decreased drug absorption and decreased therapeutic benefit. Of recently approved orally administered cancer therapeutics, >50% are characterized as having pH-dependent solubility, but there are currently no data describing the potential for this ARA-DDI liability among targeted agents currently in clinical development. The objectives of this study were to (1) determine the prevalence of ARA use among different cancer populations and (2) investigate the prevalence of orally administered cancer therapeutics currently in development that may be liable for an ARA-DDI. To address the question of ARA use among cancer patients, a retrospective cross-sectional analysis was performed using two large healthcare databases: Thomson Reuters MarketScan (N = 1,776,443) and the U.S. Department of Veterans Affairs (VA, N = 1,171,833). Among all cancer patients, the total prevalence proportion of ARA use (no. of cancer patients receiving an ARA/total no. of cancer patients) was 20% and 33% for the MarketScan and VA databases, respectively. PPIs were the most commonly prescribed agent, comprising 79% and 65% of all cancer patients receiving a prescription for an ARA (no. of cancer patients receiving a PPI /no. of cancer patients receiving an ARA) for the MarketScan and VA databases, respectively. To estimate the ARA-DDI liability of orally administered molecular targeted cancer therapeutics currently in development, two publicly available databases, (1) Kinase SARfari and (2) canSAR, were examined. For those orally administered clinical candidates that had available structures, the pKa's and corresponding relative solubilities were calculated for a normal fasting pH of 1.2 and an "ARA-hypochlorhydric" pH of 4. Taking calculated pKa's and relative solubilities into consideration, clinical candidates were classified based on their risk for an ARA-DDI. More than one-quarter (28%) of the molecules investigated are at high risk for an ARA-DDI, and of those high risk molecules, nearly three-quarters (73%) are being clinically evaluated for at least one of five cancer types with the highest prevalence of ARA use (gastrointestinal, pancreatic, lung, glioblastoma multiforme, gastrointestinal stromal tumor (GIST)). These data strongly suggest that with the clinical development of ARA-DDI-susceptible cancer therapeutics will come continued challenges for drug-development scientists, oncologists, and regulatory agencies in ensuring that patients achieve safe and efficacious exposures of their cancer therapeutics and thus optimal patient outcomes.

[1]  J. Lewis,et al.  Chronic proton pump inhibitor therapy and the risk of colorectal cancer. , 2007, Gastroenterology.

[2]  E. Giovannetti,et al.  A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[3]  A. Paci,et al.  Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. , 2011, European journal of cancer.

[4]  R. Hunt,et al.  Management of Reflux Symptoms with Over-the-Counter Proton Pump Inhibitors: Issues and Proposed Guidelines , 2009, Digestion.

[5]  M. Egorin,et al.  Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. , 2009, British journal of clinical pharmacology.

[6]  G. Coté,et al.  Potential adverse effects of proton pump inhibitors , 2008, Current gastroenterology reports.

[7]  T. Misawa,et al.  Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients. , 2010, Journal of palliative medicine.

[8]  E. Wiemer,et al.  Drug Transporters and Imatinib Treatment: Implications for Clinical Practice , 2010, Clinical Cancer Research.

[9]  J. Ware,et al.  Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl. , 2013, Molecular pharmaceutics.

[10]  Silvia Duong,et al.  Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[11]  A. Tan,et al.  Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[12]  A. Nagler,et al.  Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC , 2012, Hematological oncology.

[13]  L. Benet,et al.  Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. , 2013, Molecular pharmaceutics.

[14]  G. Sachs,et al.  Synthesis or rupture: duration of acid inhibition by proton pump inhibitors. , 2003, Drugs of Today.

[15]  A. Sanil,et al.  Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects , 2009, Journal of clinical pharmacology.

[16]  Loriano Storchi,et al.  New and Original pKa Prediction Method Using Grid Molecular Interaction Fields , 2007, J. Chem. Inf. Model..

[17]  Manfred Kansy,et al.  Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series. , 2010, European journal of medicinal chemistry.

[18]  P. Kluetz,et al.  Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. , 2012, The oncologist.

[19]  J. Ware,et al.  Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH‐Dependent Solubility the Achilles Heel of Targeted Therapy? , 2012, Clinical pharmacology and therapeutics.

[20]  M. Baccarani,et al.  Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial , 2012, Haematologica.

[21]  M. Egorin,et al.  Effect of antacid on imatinib absorption , 2009, Cancer Chemotherapy and Pharmacology.

[22]  C. Metge,et al.  The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use , 2007, The American Journal of Gastroenterology.

[23]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .